title: Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC.
abstract: Motzer and colleagues present updated results from a multicenter, phase III trial of sunitinib versus interferon-alpha as first-line treatment for patients with metastatic renal-cell carcinoma. The observed improvement in overall survival for patients treated with sunitinib further establishes this agent as the reference standard for first-line treatment of good-risk and intermediate-risk patients with metastatic renal cancer.
authors.affiliation: Massachusetts General Hospital Cancer Center, The Claire and John Bertucci Center for Genitourinary Cancers, 55 Fruit Street, Boston, MA 02114, USA.
authors.forename: Jason E
authors.initials: JE
authors.lastname: Faris
authors.forename: M Dror
authors.initials: MD
authors.lastname: Michaelson